Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Idiopathic pulmonary fibrosis, mortality, hospitalization, health care costs, administrative data, drugs, statutory health insurance
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 October 2021
|
| In: |
Respiratory research
Year: 2021, Volume: 22, Pages: 1-11 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-021-01857-y |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-021-01857-y Resolving-System, kostenfrei: https://doi.org/10.1186/s12931-021-01857-y Resolving-System, kostenfrei: https://doi.org/10.25673/110784 
|
| Author Notes: | Pavo Marijic, Larissa Schwarzkopf, Lars Schwettmann, Thomas Ruhnke, Franziska Trudzinski and Michael Kreuter |
| Summary: | Idiopathic pulmonary fibrosis, mortality, hospitalization, health care costs, administrative data, drugs, statutory health insurance Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither evidence from prospective data nor a guideline recommendation, which drug should be preferred over the other. This study aimed to compare pirfenidone and nintedanib-treated patients regarding all-cause mortality, all-cause and respiratory-related hospitalizations, and overall as well as respiratory-related health care costs borne by the Statutory Health Insurance (SHI). |
|---|---|
| Item Description: | Gesehen am 30.12.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-021-01857-y |